MedTrace Logo

The Immunogenicity and Persistence of Booster Dose With Hepatitis B Vaccine in College Students

NCT05099757 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2021-12-06

No results posted yet for this study

Summary

The anti-HBs produced after hepatitis B vaccination will decrease over time. College students are vaccinated with hepatitis B vaccine at birth, and their antibodies may have decreased significantly. In addition, college students are sexually active population, which has a high risk of HBV infection. It is necessary to study the anti-HBs level of college students, and analyze the strengthening immunization for this special group.

This study will analyze the immunogenicity, immune persistence, and safety of booster dose of intramuscular 20 µg recombinant hepatitis B vaccines. Different booster vaccination including one-dose (0 month), two-dose (0, 1 months), or three-dose (0, 1, and 6 months) was given according to the antibody production level after booster vaccination among college students.

Conditions

  • Hepatitis B Vaccine

Interventions

BIOLOGICAL

20 µg dose hepatitis B vaccine

one-dose, two-dose or three-dose, 20 µg per dose

Sponsors & Collaborators

  • Shanxi Medical University

    lead OTHER

Principal Investigators

  • Suping Wang, PhD · Shanxi Medical University

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-20
Primary Completion
2022-11-25
Completion
2023-12-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05099757 on ClinicalTrials.gov